Mika Derynck
Director/Miembro de la Junta en ENLIVEN THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de Mika Derynck
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director/Miembro de la Junta | 23/02/2023 | - |
| Independent Dir/Board Member | 23/02/2023 | - | |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Director/Miembro de la Junta | 19/01/2022 | - |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Director Técnico/Científico/I+D | - | - |
Historial de carrera de Mika Derynck
Formación de Mika Derynck.
| Boston University | Undergraduate Degree |
| Boston University School of Medicine | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Israel | 2 |
Operativa
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Independent Dir/Board Member | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Mika Derynck
- Experiencia
